Current Report Filing (8-k)
February 11 2015 - 4:43PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 11, 2015 (November 26, 2014)
ALTAIR INTERNATIONAL CORP.
(Exact name of registrant as specified in its
charter)
Nevada |
|
333-190235 |
|
99-0385465 |
(State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
of Incorporation) |
|
|
|
Identification Number) |
|
|
|
|
|
6501 E. Greenway Pkwy #103-412
Scottsdale, AZ 85254
(760) 413-3927
(Address, including
zip code, and telephone number, including area code,
of registrant's principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ALTAIR INTERNATIONAL CORP.
Form 8-K
Current Report
Item 1.01 Entry into a Material Definitive
Agreement.
On November 26, 2014, Altair
International Corp., a corporation organized and existing under the laws of the State of Nevada (“Altair”), and Cure
Pharmaceutical Corporation, a corporation organized and existing under the laws of the State of California (“Supplier”)
entered into an Exclusive Distribution and License Agreement (the “Distribution Agreement”). Pursuant to the Distribution
Agreement, Altair was appointed as the exclusive distributor and licensee, to distribute, offer for sale and sell an Oral Thin
Film (OTF) delivery system, which will include the drug active sildenafil in various dosage amounts manufactured and developed
by Supplier. The Company has the exclusive rights to sell the product throughout the defined territory, which includes Asia, Brazil,
the Middle East and Canada. For the sake of clarity, Asia includes India, China, Malaysia, Indonesia, Taiwan, Japan, Philippines,
and those other countries dependent on China’s SDA certification for their approval protocol of the Products. Further, Supplier
acknowledges and agrees that Altair has the right to appoint sub-distributors (which may be Affiliates of Altair), as determined
from time to time in Altair’s sole discretion, to distribute, offer for sale and sell the Products in the Territory.
Additionally, Supplier
granted to Altair the exclusive license, for the duration of the Term, with the right to grant sub-licenses to sub-distributors,
under the Product Trademarks to distribute, offer for sale and sell the Products in the Territory.
In accordance with the
foregoing and in order to close the transaction, Altair paid Supplier a license and distribution fee in the aggregate amount of
Two Hundred Thousand ($200,000) Dollars (the “License Fee). The Final Payment was made to Supplier on January 20, 2015. All
closing certificates and final due diligence documents were received and the Transaction closed on February 10, 2015.
The foregoing description
of the Distribution Agreement is not complete and is qualified in its entirety by reference to the full text of the Distribution
Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated by reference into this Item 1.01.
Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information regarding the Distribution Agreement
is included in Item 1.01 above is incorporated by reference into this Item 2.03.
Item 8.01 Other Events
On February 9, 2015, the
“Company effectuated a forward stock split (the “Forward Split”) of its issued and outstanding common shares
whereby every one (1) old share of the Company’s common stock was exchanged for seven (7) new shares of the Company's common
stock. FINRA confirmed approval of the Forward Split on February 9, 2015, payable as a dividend to shareholders, and the Forward
Split became effective the same day. The Forward Split shares are payable upon surrender of certificates to the Company's transfer
agent. Accordingly, the Company’s symbol will change to ATAOD to reflect the Forward Split and twenty (20) days thereafter,
the “D” will be removed and the symbol will return to ATAO.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ALTAIR INTERNATIONAL CORP. |
|
|
|
|
|
|
Date: February 11, 2015 |
By: |
/s/ Alan Smith |
|
|
Alan Smith |
|
|
Chief Executive Officer |
Altair (QB) (USOTC:ATAO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Altair (QB) (USOTC:ATAO)
Historical Stock Chart
From Jul 2023 to Jul 2024